Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.77 |
| ▸ | CA2 | P00918 | 5/20 | 0.77 |
| ▸ | CA12 | O43570 | 4/20 | 0.77 |
| ▸ | CA7 | P43166 | 4/20 | 0.77 |
| ▸ | CA9 | Q16790 | 4/20 | 0.77 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.77 |
| ▸ | XDH | P47989 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10034770 | 0.91 | CA12 (0.65) | CA1CA2CA12CA7CA9 | |
| SCHEMBL18822001 | 0.88 | EGFR (0.73) | CA1CA2CA12CA7CA9 | |
| Methyl Protocatechuate SCHEMBL38624 | 0.87 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Methyl Protocatechuate SCHEMBL29360855 | 0.87 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| SCHEMBL408614 | 0.86 | XDH (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL14832783 | 0.85 | EGFR (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL68289 | 0.84 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| SCHEMBL69304 | 0.84 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| SCHEMBL410169 | 0.83 | CA12 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30809635 | 0.83 | CA1 (0.71) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | CA1 4869/4885CA2 4781/4885CA12 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.